Benefits of cocrystallisation in pharmaceutical materials science: an update.
about
Improved Stability and Smart-Material Functionality Realized in an Energetic CocrystalCrystal engineering rescues a solution organic synthesis in a cocrystallization that confirms the configuration of a molecular ladder.Cocrystallization for successful drug delivery.Ionic liquids in drug delivery.4-Carbamoylpyridin-1-ium 2,2,2-trichloro-acetate.4-Carbamoylpyridin-1-ium 2,2,2-tri-chloro-acetate-isonicotinamide (1/1)Stereoselectivity in the salt-cocrystal products formed by phenylglycinol or phenylglycine with their respective sodium or hydrochloride salts.Thermally activated intermixture in pentacene-perfluoropentacene heterostructures.DNP-enhanced solid-state NMR spectroscopy of active pharmaceutical ingredients.Introductory lecture: Mechanochemistry, a versatile synthesis strategy for new materials.Survival of the Fittest: Competitive Co-crystal Reactions in the Ball Mill.Structural studies of crystalline forms of triamterene with carboxylic acid, GRAS and API molecules.Dealing with crystal forms (the Kingdom of Serendip?)Synthesis, structure determination, and formation of a theobromine : oxalic acid 2 : 1 cocrystalEvaluation of the formation pathways of cocrystal polymorphs in liquid-assisted synthesesMechanochemical synthesis and characterisation of cocrystals and metal organic compoundsBuilding multi-component crystals from cations and co-crystals: the use of chaperones
P2860
Q29042596-03160289-FAB8-40A4-BBC6-1EEEA36EC4C5Q35091038-FC475372-20A0-4A6B-8C1C-346782FAA3CFQ38068972-BCDB1561-09B3-47FA-8D46-84667B96D8D2Q38116530-459348D7-F23D-40F9-AF56-8AFE55B34000Q42323555-501D190C-9451-4C22-A3CB-6B4F3393F633Q42323603-A49DFFE3-62C9-48A7-A9A6-6A0E2B6A4BCCQ43630008-E1B72B60-B143-4E98-A405-3F1585315979Q44502395-773B3CB7-534C-41D3-B7D9-88D67ED8A045Q47807784-0E8B7256-A94B-43BF-9B94-50D153AF50F7Q48520512-F5790419-846D-4304-9338-4471E309EF2BQ51786790-E9E1BC0C-04D6-440E-B4CA-8B190098FC44Q55394847-D85CC04C-B0DC-4163-8A4E-316A779BDA9BQ56984531-9DE65BB6-604D-4C00-8B21-2D661EA889F0Q57599097-511719CE-B167-4150-A884-215E208E7BF5Q57599103-F5269D95-C13E-4193-9BC1-46780F67261AQ57599110-CB646400-62D0-45AE-A0B8-528DEB4A8BB9Q57790857-405EFF6C-70C6-4515-86BD-763FB4B8F543
P2860
Benefits of cocrystallisation in pharmaceutical materials science: an update.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Benefits of cocrystallisation in pharmaceutical materials science: an update.
@en
Benefits of cocrystallisation in pharmaceutical materials science: an update.
@nl
type
label
Benefits of cocrystallisation in pharmaceutical materials science: an update.
@en
Benefits of cocrystallisation in pharmaceutical materials science: an update.
@nl
prefLabel
Benefits of cocrystallisation in pharmaceutical materials science: an update.
@en
Benefits of cocrystallisation in pharmaceutical materials science: an update.
@nl
P2860
P1476
Benefits of cocrystallisation in pharmaceutical materials science: an update.
@en
P2093
William Jones
P2860
P304
P356
10.1111/J.2042-7158.2010.01133.X
P577
2010-11-01T00:00:00Z